The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo

BACKGROUND: Treatment options for patients with recurrent superficial bladder cancer are limited, necessitating aggressive exploration of new treatment strategies that effectively prevent recurrence and progression to invasive disease. We assessed the effects of belinostat (previously PXD101), a nov...

Descripción completa

Detalles Bibliográficos
Autores principales: Buckley, Michael T, Yoon, Joanne, Yee, Herman, Chiriboga, Luis, Liebes, Leonard, Ara, Gulshan, Qian, Xiaozhong, Bajorin, Dean F, Sun, Tung-Tien, Wu, Xue-Ru, Osman, Iman
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2100044/
https://www.ncbi.nlm.nih.gov/pubmed/17935615
http://dx.doi.org/10.1186/1479-5876-5-49

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2100044/
https://www.ncbi.nlm.nih.gov/pubmed/17935615
http://dx.doi.org/10.1186/1479-5876-5-49

Ejemplares similares